HIV药物市场规模、份额、成长分析（按药物类别、药物类型、分销管道和地区）－2025-2032年产业预测

预计 2023 年全球爱滋病治疗药物市场价值将达到 345.7 亿美元，从 2024 年的 360.9 亿美元增长到 2032 年的 509.3 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.4%。

由于全球爱滋病毒感染者人数不断增加，预计爱滋病毒药物市场将出现强劲成长。人们对爱滋病毒认识的提高以及对先进治疗方案的需求不断增长预计将在未来几年进一步促进销售。抗逆转录病毒疗法 (ART) 的创新，受到对增强型爱滋病毒药物开发的大量投资的推动，将对市场产生重大影响。政府致力于提高人们对爱滋病毒的认识和预防，预计将在长期内支持药品销售，而对早期检测和诊断的重视将为製药公司创造新的机会。然而，抗药性、副作用、社会耻辱以及某些治疗方法的高成本等挑战可能会阻碍 2031 年以后的整体市场需求。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析
• 专利分析

HIV药物市场规模（按药物类别和复合年增长率）(2025-2032)

• 市场概览
• 多重用药
• 核苷类似物逆转录酶抑制剂（NRTI）
• 非核苷逆转录酶抑制剂（NNRTI）
• 进入和融合抑制剂
• 蛋白酶抑制剂（PI）
• 整合酶抑制剂
• 辅助受体拮抗剂

HIV药物市场规模（按药物类型和复合年增长率）(2025-2032)

• 市场概览
• 品牌药品
• 学名药

HIV药物市场规模（依分销管道及复合年增长率）(2025-2032)

• 市场概览
• 医院药房
• 零售药局
• 网路药局
• 其他的

HIV治疗药物市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

    主要企业简介

    • 吉利德科学公司（美国）
    • ViiV Healthcare（英国）
    • 默克公司（美国）
    • 百时美施贵宝公司（美国）
    • 艾伯维公司（美国）
    • 勃林格殷格翰国际有限公司（德国）
    • F. Hoffmann-La Roche AG（瑞士）
    • 西普拉公司（印度）
    • 梯瓦製药工业股份有限公司（以色列）
    • 异性恋药物（印度）
    • 巴塞利亚製药公司（瑞士）
    • Advanz Pharma（英国）
    • 太阳製药工业有限公司（印度）
    • 奥罗宾多製药（印度）
    • 雷迪博士实验室（印度）
    • 鲁宾有限公司（印度）
    • 麦克劳兹製药有限公司（印度）
    • Glenmark 製药公司（印度）
    • Torrent Pharmaceuticals Ltd.（印度）
    • Zydus Lifesciences Limited（印度）

结论和建议

Global HIV Drugs Market size was valued at USD 34.57 billion in 2023 and is poised to grow from USD 36.09 billion in 2024 to USD 50.93 billion by 2032, growing at a CAGR of 4.4% during the forecast period (2025-2032).

The rising global prevalence of HIV infections is set to drive strong growth in the HIV drugs market. Increased awareness of HIV, alongside growing demand for advanced treatment options, is expected to further elevate sales in the coming years. Innovations in antiretroviral therapy (ART) will significantly influence the market, supported by substantial investment in the development of enhanced HIV therapeutics. Government initiatives focused on HIV awareness and prevention are anticipated to support long-term drug sales, while an emphasis on early testing and diagnostics opens new business opportunities for pharmaceutical companies. However, challenges such as drug resistance, side effects, social stigma, and the high cost of certain treatments may hinder overall demand in the market landscape through 2031 and beyond.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hiv Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hiv Drugs Market Segments Analysis

Global HIV Drugs Market is segmented by Medication Class, Drug Type, Distribution Channel and region. Based on Medication Class, the market is segmented into Multi-class Combination Drugs, Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry & Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors and Coreceptor Antagonists. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hiv Drugs Market

The global HIV drugs market is being propelled by the proactive initiatives launched by governments and public health organizations aimed at enhancing awareness and support for HIV treatment. These programs are designed to increase accessibility to HIV medications for patients worldwide, with a particular focus on aiding individuals in low- to middle-income countries. By improving the reach and availability of these essential drugs, these initiatives are anticipated to significantly benefit affected populations, ultimately contributing to better health outcomes and reduced transmission rates in diverse regions across the globe.

Restraints in the Global Hiv Drugs Market

Drug resistance represents a significant challenge within the global HIV drugs market, posing a serious constraint on its growth prospects. The emergence of drug-resistant HIV strains is primarily driven by inconsistent adherence to prescribed medication regimens. This situation not only narrows treatment options available to patients but also complicates disease management strategies. Furthermore, the necessity for alternative therapies to combat these resistant strains slows down the overall potential for market expansion. As a result, addressing the issue of drug resistance is critical for the sustained development and effectiveness of HIV treatment solutions in the global healthcare landscape.

Market Trends of the Global Hiv Drugs Market

The global HIV drugs market is increasingly leaning towards dual therapy as a strategic trend, with pharmaceutical companies seizing the opportunity to enhance patient outcomes while minimizing side effects associated with traditional antiretroviral treatments. This trend not only addresses the growing demand for reduced toxicity but also alleviates the pill burden that patients face, promoting better adherence to treatment regimens. As regulatory bodies continue to support innovative treatment approaches, dual therapy is positioned to gain traction, allowing companies to expand their business scope and cater to a more health-conscious consumer base, thus reshaping the landscape of HIV management in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global HIV Drugs Market Size by Medication Class & CAGR (2025-2032)

• Market Overview
• Multi-class Combination Drugs
• Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
• Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Entry & Fusion Inhibitors
• Protease Inhibitors (PIs)
• Integrase Inhibitors
• Coreceptor Antagonists

Global HIV Drugs Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Branded Drugs
• Generic Drugs

Global HIV Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global HIV Drugs Market Size & CAGR (2025-2032)

• North America (Medication Class, Drug Type, Distribution Channel)
  • US
  • Canada
• Europe (Medication Class, Drug Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Medication Class, Drug Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Medication Class, Drug Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Medication Class, Drug Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViiV Healthcare (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero Drugs (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Basilea Pharmaceutica (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanz Pharma (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macleods Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations